Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGF-βRI), is the only known TGF-β pathway inhibitor. In the present study, we investigated the effect of galunisertib o
No correlation was found among CD133+ EVs and ischemia time, introduction of calcineurin inhibitors (CNI), HLA mismatches, and pre-transplant diuresis. Data are expressed are median [min-max], p* = Ma
Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can
